The FDA approved dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) with Oncomine Dx Target Test (Thermo Fisher Scientific) for treatment-naive and previously treated patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC).
Significant Information:
- First targeted treatment in the U.S. for BRAF V600E–mutant metastatic NSCLC
- BRAF mutations appear in approximately 1% to 3% of NSCLC cases worldwide
- BRAF V600E is an aggressive